Market Capitalization: YmAbs (YMAB)

Y-mAbs Therapeutics (YMAB) focuses on developing targeted therapies for children by leveraging strategic alliances and the acquisition of antibody patents. This price chart on GURU.Markets, where the market capitalization stands at 0.39, complements data regarding the collaboration with the Memorial Sloan Kettering center to develop new drugs. Stable sales of approved treatments provide the cash flow necessary to fund ongoing scientific research.

ymabs.com - YMAB Market Value (period 07/04/2022 - 09/27/2025)

Metric breakdowns and analytics for Y-mAbs Corp (YMAB)

- market price and analyst price targets:

Price Chart Y-mAbs Therapeutics, Inc.|YMAB - Consensus Target

- company stock exchange capitalization indicators:

Market Capitalization Y-mAbs Corp|YMAB - Enterprise Value

- issuer book value statistics:

Book Value per Share Y-mAbs Therapeutics|YMAB - Company Book Value|Market Capitalization to Book Value Ratio ymabs.com|YMAB - Cumulative Company Assets

- issuer credit burden and liquidity indicators:

- financial results and valuation multiples details:

YMAB - Final Profit|Future Profit Y-mAbs Therapeutics|YMAB - Company Value to Net Income|Forward P/E Multiple YmAbs|YMAB - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Y-mAbs Corp|YMAB - Operating profit EBITDA|Earnings per share for the last twelve months Y-mAbs Therapeutics|YMAB - Earnings per share for the trailing year|Quarterly EPS earnings growth ymabs.com|YMAB - Earnings per share growth rate in current year|Expected earnings per share growth for next year Y-mAbs Therapeutics

Fundamental company valuation:Y-mAbs Therapeutics, Inc. YMAB

Market capitalization is calculated as the product of the current share price and the total number of outstanding shares. This aggregate metric reflects the market's collective valuation of all the issuer's assets and future cash flows. For Y-mAbs Therapeutics (YMAB), the volatility of this metric is driven by geopolitical barriers that hinder the export of oncology drugs and the conduct of international trials. The company's market capitalization trend on the exchange reflects investor reaction to these logistical risks. A stable trend in this curve confirms the viability of the business model.

Competitors of Y-mAbs Therapeutics (YMAB)